Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
⚠️ Updated analysis. Primary endpoints were previously reported. This analysis reports updated DFS, OS, and safety at median follow-up of 8 years (SOFT) and 9 years (combined SOFT+TEXT).
🎯 Clinical Bottom Line
Adding ovarian function suppression (OFS) to tamoxifen significantly improves DFS and OS in premenopausal women with HR+ early breast cancer. Substituting exemestane for tamoxifen with OFS further improves DFS — including distant recurrence — without an OS difference over tamoxifen+OFS. Benefits are greatest in higher-risk, chemotherapy-treated patients.
Key Result 1 (SOFT primary, ITT): 8-yr DFS — tamoxifen+OFS 83.2% vs tamoxifen alone 78.9%, HR 0.76 (95% CI 0.62–0.93; P=0.009)
Key Result 2 (Combined SOFT+TEXT, ITT): 8-yr DFS — exemestane+OFS 86.8% vs tamoxifen+OFS 82.8%, HR 0.77 (95% CI 0.67–0.90; P<0.001)
Key Result 3 (SOFT, ITT): 8-yr OS — tamoxifen+OFS 93.3% vs tamoxifen alone 91.5%, HR 0.67 (95% CI 0.48–0.92; P=0.01)
Safety Signal: Musculoskeletal symptoms grade 3/4 in 11.4% with exemestane+OFS; osteoporosis (T score <−2.5) in 14.8% with exemestane+OFS. ~20% early triptorelin discontinuation.
✅ Patient Eligibility
Must Have:
-
Premenopausal status (documented estradiol level)
-
HR-positive breast cancer (ER or PR ≥10%)
-
Operable early-stage disease
Cannot Have:
-
Postmenopausal status
-
Contraindications to endocrine therapy or ovarian suppression
💊 Dosing Quick Guide
Tamoxifen Alone (SOFT only — lower-risk option)
Tamoxifen: 20 mg PO daily × 5 years
Tamoxifen + Ovarian Suppression
Tamoxifen: 20 mg PO daily × 5 years
Triptorelin: 3.75 mg IM every 28 days × 5 years (or oophorectomy/ovarian irradiation)
Exemestane + Ovarian Suppression
Exemestane: 25 mg PO daily × 5 years
Triptorelin: 3.75 mg IM every 28 days × 5 years (or oophorectomy/ovarian irradiation)
Key Monitoring [2]
-
Baseline and serial DXA scans — especially with exemestane+OFS
-
Blood pressure monitoring (hypertension grade 3/4: 5.7–8.1%)
-
Depression and sexual function screening
-
Estradiol levels to confirm ovarian suppression adequacy
⚠️ Safety Snapshot
| Grade 3/4 Targeted AE | Tamoxifen Alone (n=1,005) | Tamoxifen+OFS (n=2,326) | Exemestane+OFS (n=2,317) |
|---|---|---|---|
| Any grade 3/4 targeted AE | 247 (24.6%) | 721 (31.0%) | 748 (32.3%) |
| Hot flushes | 78 (7.8%) | 284 (12.2%) | 234 (10.1%) |
| Musculoskeletal symptoms | 67 (6.7%) | 132 (5.7%) | 263 (11.4%) |
| Hypertension | 57 (5.7%) | 188 (8.1%) | 168 (7.3%) |
| Depression | 41 (4.1%) | 108 (4.6%) | 95 (4.1%) |
| Thrombosis/embolism | 17 (1.7%) | 47 (2.0%) | 20 (0.9%) |
| Fracture | 8 (0.8%) | 23 (1.0%) | 37 (1.6%) |
⚠️ Osteoporosis (T score <−2.5): 3.9% tamoxifen alone; 7.2% tamoxifen+OFS; 14.8% exemestane+OFS
Key safety metrics:
-
Early oral endocrine discontinuation: 22.5% (T) / 19.3% (T+OFS) / 23.7% (E+OFS)
-
Early triptorelin cessation: 19.0% (combined population)
-
Grade 5 event: 1 cardiac event (tamoxifen alone); no others reported
📊 Key Numbers
Median follow-up: 8 years (SOFT); 9 years (combined SOFT+TEXT)
SOFT — Tamoxifen+OFS vs Tamoxifen Alone
| Outcome | Tamoxifen Alone | Tamoxifen+OFS | HR (95% CI) | p-value |
|---|---|---|---|---|
| 8-yr DFS | 78.9% | 83.2% | 0.76 (0.62–0.93) | P=0.009 |
| 8-yr distant recurrence-free | 88.4% | 89.4% | 0.86 (0.66–1.13) | P=0.28 |
| 8-yr OS | 91.5% | 93.3% | 0.67 (0.48–0.92) | P=0.01 |
Combined SOFT+TEXT — Exemestane+OFS vs Tamoxifen+OFS
| Outcome | Tamoxifen+OFS | Exemestane+OFS | HR (95% CI) | p-value |
|---|---|---|---|---|
| 8-yr DFS | 82.8% | 86.8% | 0.77 (0.67–0.90) | P<0.001 |
| 8-yr distant recurrence-free | 89.7% | 91.8% | 0.80 (0.66–0.96) | P=0.02 |
| 8-yr OS | 93.3% | 93.4% | 0.98 (0.79–1.22) | P=0.84 |
SOFT Chemotherapy Cohort (highest-risk population)
| Outcome | T Alone | T+OFS | E+OFS |
|---|---|---|---|
| 8-yr DFS | 71.4% | 76.7% | 80.4% |
| 8-yr OS | 85.1% | 89.4% | 87.2% |
🔬 Key Comparator Context
| Trial | Regimen | Population | Key Result | Ref |
|---|---|---|---|---|
| SOFT | T+OFS vs T alone | Premenopausal HR+ early BC | 8-yr DFS HR 0.76 (P=0.009); OS HR 0.67 (P=0.01) | [1] |
| ABCSG-12 | Goserelin+anastrozole vs goserelin+tamoxifen | Premenopausal HR+ early BC | No DFS benefit for AI; OS numerically favored T+OFS | [4] |
| ASTRRA | T+OFS vs T alone (post-chemo) | Premenopausal HR+ early BC | DFS improved with OFS; see [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Chemotherapy-treated (SOFT): 8-yr DFS 71.4% (T) vs 76.7% (T+OFS) vs 80.4% (E+OFS) — largest absolute benefit in this higher-risk group
HER2-positive (SOFT, T+OFS vs T): HR 0.41 (95% CI 0.22–0.75), interaction P=0.04 — particular benefit from OFS with tamoxifen
HER2-negative combined (E+OFS vs T+OFS): DFS HR 0.70 (0.60–0.83); distant recurrence HR 0.69 (0.56–0.85) — strong signal in the majority subtype
No chemotherapy (SOFT, E+OFS vs T): HR 0.56 (0.36–0.86) — benefit extends to lower-risk patients, though absolute differences smaller
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Tamoxifen: approved for adjuvant HR+ BC. Exemestane: approved for sequential adjuvant use in postmenopausal women; use with OFS in premenopausal women is guideline-supported. Triptorelin: approved for prostate cancer; OFS use is off-label (goserelin approved for premenopausal BC). [2] |
⚠️ Verify current regulatory status before prescribing.
NCCN: Recommends OFS + tamoxifen or AI for higher-risk premenopausal HR+ early BC (Category 1) [3]
⚡ Grey Zones
-
Optimal duration of ovarian suppression (5 years? shorter?) is unknown
-
Tamoxifen-alone arm may not reflect 2026 practice (no extended endocrine therapy)
-
OS data still immature — maximal separation expected beyond 10 years
-
Genomic assay integration (Oncotype DX) for OFS decision-making not established
-
Paradox: tamoxifen+OFS showed OS benefit over tamoxifen alone (P=0.01) but exemestane+OFS did not (HR 0.85; CI crosses 1.0)
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at Full Version
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
1. Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018. doi:10.1056/NEJMoa1803164
2. Exemestane (Aromasin) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. Accessed March 2026.
4. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313-320.
5. Kim HA, Lee JW, Nam SJ, et al. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial (ASTRRA). J Clin Oncol. 2020;38(5):434-443.